Prognosis
Pfizer Scaled Back Vaccine Output Targets Earlier This Year
- Drugmaker cut production goal to 50 million doses in November
- Previous target was 100 million doses by the close of 2020
This article is for subscribers only.
Pfizer Inc. scaled back its Covid-19 production targets earlier this year after the drugmaker ran into difficulties securing all the materials it needs to produce the shots at a large scale.
In news releases through September, Pfizer had said that it aimed to manufacture up to 100 million vaccine doses this year. But in several releases in November, the company cut that to an estimate of up to 50 million doses. Pfizer is developing its vaccine with Germany-based BioNTech SE.